NLS Pharmaceutics and Kadimastem Finalize Merger and Future Plans

Exciting Developments for NLS Pharmaceutics and Kadimastem

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and Kadimastem Ltd. (TASE: KDST) have announced significant advancements regarding their proposed merger. This merger presents a unique opportunity for both companies to enhance their positions in the biopharmaceutical marketplace, focusing on innovative therapies aimed at treating central nervous system disorders and neurodegenerative diseases.

Understanding the Merger Dynamics

The announcement reveals that all essential conditions precedent for the merger have either been fulfilled or waived by the involved parties. With Nasdaq's approval for NLS Pharmaceutics, both companies are prepared for the next steps leading up to the merger, making it a historical point for their operations.

Timeline and Key Dates

The merger is strategically planned for completion on October 30, 2025, a date that marks a transformative moment for NLS and Kadimastem. Following this, Kadimastem’s ordinary shares will be delisted from the Tel Aviv Stock Exchange, with trading suspended until the merger is finalized. This step illustrates the companies’ commitment to streamline their operations and focus on the successful integration of their respective business models.

New Stock Symbol and Share Exchange Ratio

Upon completing the merger, the newly formed company will operate under the name NewCelX Ltd., with its common shares listed on the Nasdaq Capital Market under the symbol "NCEL." This name change coincides with a pivotal exchange ratio established at 7.06 NLS common shares for each Kadimastem ordinary share. After a reverse share split of NLS’s common shares, the final ratio will rest at 0.706 NLS common shares per Kadimastem ordinary share.

Trading Availability and Transition

Shareholders can expect the new common shares, previously NLS common shares, to be deposited into their accounts following market hours on November 3, 2025. Trading for these shares on the Nasdaq is slated to commence on November 4, 2025. This transition is crucial for ensuring that shareholders are integrated into the new corporate structure smoothly. As the merger progresses, both companies are committed to keeping their shareholders informed of any developments.

About NLS Pharmaceutics

NLS Pharmaceutics Ltd. specializes in creating groundbreaking therapies for neurological disorders. With a robust pipeline and strong commitment to innovation, NLS is well-positioned to address unmet medical needs in the clinical landscape. Their detailed focus on CNS disorders showcases their dedication to advancing healthcare solutions that can significantly improve patient lives.

About Kadimastem

Kadimastem Ltd. stands at the forefront of cell therapy innovation, developing off-the-shelf cell products specifically targeting neurodegenerative diseases and diabetes. Their approach emphasizes accessibility and efficacy, making strides toward effective treatment options for patients suffering from chronic conditions.

Social Media Presence

Both companies maintain active engagement on various social platforms, ensuring they keep their followers updated. Interested parties can find NLS Pharmaceutics on LinkedIn and Kadimastem on multiple platforms including Facebook and Instagram, promoting transparency and accessibility in communication.

Frequently Asked Questions

What is the date of the merger completion?

The merger is set to be completed on October 30, 2025.

What will be the new name of the combined company?

The combined company will be called NewCelX Ltd.

What trading symbol will the new company use?

The new company will be listed under the ticker symbol "NCEL" on the Nasdaq Capital Market.

What is the exchange ratio for the shares?

The final exchange ratio is set at 0.706 NLS common shares for each Kadimastem ordinary share.

How will shareholders receive their new shares?

New shares are expected to be deposited into Kadimastem shareholders' accounts after trading hours on November 3, 2025.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.